个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共37条记录   Resveratrol: Challenges in Translation to the Clinic - A Critical Discussion [作者：Subramanian, L; Youssef, S; Bhattacharya, S; Kenealey, J; Polans, AS; van Ginkel, PR,期刊：Clinical Cancer Research, 页码：5942-5948 , 文章类型： Review，,卷期：2010年16-24] Low cancer survival rates and the serious side effects often associated with current chemotherapeutics highlight the need for new and effective nontoxic anticancer agents. Since 1997 when Jang and colleagues first descri... Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease [作者：Bates, SE,期刊：Clinical Cancer Research, 页码：5950-5950 , 文章类型： Editorial Material，,卷期：2010年16-24] Translating Clinical Trials into Meaningful Outcomes [作者：LoRusso, PM; Schnipper, LE; Stewart, DJ; Boerner, SA; Averbuch, SD; Wolf, W,期刊：Clinical Cancer Research, 页码：5951-5955 , 文章类型： Article，,卷期：2010年16-24] Efforts to unravel the complex biology that is necessary to develop new therapies best suited for an individual with cancer are at a crossroads with a strained health care system and an insufficient clinical trial appara... Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? [作者：LoRusso, PM; Anderson, AB; Boerner, SA; Averbuch, SD,期刊：Clinical Cancer Research, 页码：5956-5962 , 文章类型： Article，,卷期：2010年16-24] Advances in our knowledge of the molecular mechanisms involved in cancer biology have contributed to an increase in novel target-specific oncology therapeutics. Unfortunately, clinical development of new drugs is an expe... Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past [作者：Booth, CM,期刊：Clinical Cancer Research, 页码：5963-5971 , 文章类型： Article，,卷期：2010年16-24] In the era of molecular oncology, patients still define a useful therapy as one that allows them to live longer and helps them to live better. Although patient outcomes have clearly improved as a result of randomized con... Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? [作者：Fojo, T; Parkinson, DR,期刊：Clinical Cancer Research, 页码：5972-5980 , 文章类型： Article，,卷期：2010年16-24] We describe the development and approval of biologically targeted agents in the clinic through examples chosen from the experience with inhibitors of the epidermal growth factor (EGF) and VEGF pathways. Despite extensive... Explaining Marginal Benefits to Patients, When "Marginal" Means Additional but Not Necessarily Small [作者：Smith, TJ; Hillner, BE,期刊：Clinical Cancer Research, 页码：5981-5986 , 文章类型： Article，,卷期：2010年16-24] Patients and their families want us to be realistic, honest, and caring about their prognosis and their options, even when the news is bad. Most oncologists will tell a patient if he is not curable, but not give specific... The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally [作者：Dalton, WS; Sullivan, DM; Yeatman, TJ; Fenstermacher, DA,期刊：Clinical Cancer Research, 页码：5987-5996 , 文章类型： Article，,卷期：2010年16-24] The Patient Protection and Affordable Care Act of 2010 will have a profound influence on health care in the United States, including how we conduct cancer research and cancer care delivery. For this reason, oncologists a... The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center [作者：Klamerus, JF; Bruinooge, SS; Ye, XB; Klamerus, ML; Damron, D; Lansey, D; Lowery, JC; Diaz, LA; Ford, JG; Kanarek, N; Rudin, CM,期刊：Clinical Cancer Research, 页码：5997-6003 , 文章类型： Article，,卷期：2010年16-24] Purpose: Cancer patients at Johns Hopkins undergo insurance clearance to verify coverage for enrollment to interventional clinical trials. We sought to explore the impact of insurance clearance on disparities in access t... Value and Cancer Care: Toward an Equitable Future [作者：Schnipper, LE; Meropol, NJ; Brock, DW,期刊：Clinical Cancer Research, 页码：6004-6008 , 文章类型： Article，,卷期：2010年16-24] Health care expenses in the United States are increasing inexorably. At the current rate of growth, it is anticipated that 20% of the gross national product will consist of health-related expenditures within the next dec... IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer [作者：Liu, Z; Liu, DX; Bojdani, E; El-Naggar, AK; Vasko, V; Xing, MZ,期刊：Clinical Cancer Research, 页码：6009-6018 , 文章类型： Article，,卷期：2010年16-24] Purpose: This study was designed to explore the role of IQGAP1 in the invasiveness of thyroid cancer and its potential as a novel prognostic marker and therapeutic target in this cancer. Experimental Design: We examined ... Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model [作者：Yu, P; Steel, JC; Zhang, ML; Morris, JC; Waldmann, TA,期刊：Clinical Cancer Research, 页码：6019-6028 , 文章类型： Article，,卷期：2010年16-24] Purpose: Interleukin 15 (IL-15) is a promising cytokine for immunotherapy of cancer due to its ability to stimulate the immunity of natural killer, B, and T cells. Its effectiveness, however, may be limited by inhibitory... Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma [作者：Aziz, SA; Jilaveanu, LB; Zito, C; Camp, RL; Rimm, DL; Conrad, P; Kluger, HM,期刊：Clinical Cancer Research, 页码：6029-6039 , 文章类型： Article，,卷期：2010年16-24] Purpose: Melanoma is relatively resistant to chemotherapy; improved targeting of molecules critical for cell proliferation and survival are needed. Phosphatidylinositol-3 kinase (PI3K) is an important target in melanoma;... The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations [作者：Comin-Anduix, B; Chodon, T; Sazegar, H; Matsunaga, D; Mock, S; Jalil, J; Escuin-Ordinas, H; Chmielowski, B; Koya, RC; Ribas, A,期刊：Clinical Cancer Research, 页码：6040-6048 , 文章类型： Article，,卷期：2010年16-24] Purpose: PLX4032 (RG7204), an oncogenic BRAF kinase inhibitor undergoing clinical evaluation, has high response rates in early clinical trials in patients with advanced BRAF(V600E) mutant melanoma. Combining PLX4032 with... Microenvironmental Regulation of Glioblastoma Radioresponse [作者：Jamal, M; Rath, BH; Williams, ES; Camphausen, K; Tofilon, PJ,期刊：Clinical Cancer Research, 页码：6049-6059 , 文章类型： Article，,卷期：2010年16-24] Purpose: Brain tumor xenografts initiated from human glioblastoma (GBM) stem-like cells (TSC) simulate the biological characteristics of GBMs in situ. Therefore, to determine whether the brain microenvironment affects th... The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance [作者：Schreck, KC; Taylor, P; Marchionni, L; Gopalakrishnan, V; Bar, EE; Gaiano, N; Eberhart, CG,期刊：Clinical Cancer Research, 页码：6060-6070 , 文章类型： Article，,卷期：2010年16-24] Purpose: Multiple developmental pathways including Notch, Hedgehog, and Wnt are active in malignant brain tumors such as medulloblastoma and glioblastoma (GBM). This raises the possibility that tumors might compensate fo...